Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia

Abstract Background Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited. Methods This study aimed to evaluate...

Full description

Saved in:
Bibliographic Details
Main Authors: Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Delin Kong, Jia Geng, Alex H. Chang, He Huang, Yongxian Hu
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Experimental Hematology & Oncology
Subjects:
Relapsed/refractory B-cell acute lymphoblastic leukemia
Chimeric antigen receptor
Sequential therapy
Online Access:https://doi.org/10.1186/s40164-024-00593-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40164-024-00593-5

Similar Items